Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction

Percentage of patients aged 18 years and older with a diagnosis of heart failure with a current or prior LVEF < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting or at hospital discharge

Date Reviewed: November 19, 2017
Support
    Group/Practice Individual Clinician

Measure Info

MIPS 005 NQF 0081 CMS 005 NQF Endorsed
Measure Type
Process
Measure Steward
Physician Consortium for Performance Improvement
Clinical Topic Area
Heart Failure
Care Setting
Home Care
Inpatient
Outpatient
Post-Acute Care
Data Source
Electronic Health Records
Registry

ACP supports NQF 0081: “Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction” because there is good evidence that ACE inhibitors and ARBs improve the health of people with heart failure and LVEF < 40%. The measure aligns with current guidelines and represents high-value care for patients with chronic heart failure.